A small study showed that a minimally invasive hysteroscopic surgery, combined with monthly shots of the peptide drug triptorelin, helped women under 37 with adenomyosis and failed IVF attempts get pregnant, with few complications and healthy babies.

To study the value of hysteroscopic cytoreductive surgery for adenomyotic lesions to improve reproductive outcomes. We describe a feasible and novel minimal invasive stepwise approach, which did not result in postoperative adhesion formation and restored favorable reproductive outcomes. Video article. Patients aged <37 years, diagnosed with adenomyotic lesions by ultrasound and/or magnetic resonance imaging, who after a minimum of 6 months of medical treatment (gonadotrophin releasing hormone agonist or dienogest) failed to conceive with a minimum of two embryo transfer cycles of high-quality blastocysts were included. The procedure was performed under conscious sedation, level 3b in an ambulatory surgical center. All patients received hormonal suppressive treatment (Dienogest 2 mgr per day or Triptoreline 3.75 mgr. IM once a month). Institutional Review Board approval and patient consent had been received for the study. The surgical steps included the following: MAIN OUTCOME MEASURE(S): Feasibility, reproductive outcomes, and complications (adhesions and placental disorders). Fifteen patients underwent surgery and had histological confirmation of adenomyosis. Second-look hysteroscopy was possible in 13 of 15 women (2 spontaneous pregnancies) with reassuring postoperative results, showing only mild lateral wall adhesions in three cases. Pregnancy was registered in 12 women: one early miscarriage; seven ongoing pregnancies; and four deliveries of healthy infants with normal birth weight and no placenta-related complications. (s): In contrast to the current beliefs, mini hysteroscopy can identify and selectively resect adenomyotic lesions. The described technique in this video in our series of patients resulted in optimal postoperative healing and excellent reproductive outcomes.